What This Instrument Covers
The National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment (July Update) Instrument 2026 is a technical update to the rules that govern how chemotherapy drugs are funded under the Pharmaceutical Benefits Scheme (PBS). It amends the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2024.
Duration and Status
The instrument was in force from 30 June 2026 to 12 October 2026, after which it was repealed.
What Is Not Specified
The source text does not specify exactly what changed in the schedule, what drugs or prices were affected, or why the instrument was repealed.
Administration
This instrument is administered by the Department of Health, Disability and Ageing and is most relevant to pharmacies and healthcare providers dispensing chemotherapy medicines under the PBS, rather than general small businesses.
Key Actions
- Pharmacy owners and healthcare providers dispensing PBS chemotherapy drugs can check the Federal Register of Legislation page at https://www.legislation.gov.au/F2026L00899 to view the full legislative text and explanatory statement for exact details of the amendments
- This instrument has already been repealed (current only from 30 June 2026 to 12 October 2026), so checking current PBS chemotherapy funding arrangements against whatever replaced it is advised
This is a plain-English summary for information only, not legal or compliance advice. Always check the official source or consult a qualified professional.